MCID: RRT020
MIFTS: 41

Rare Tumor

Categories: Cancer diseases, Eye diseases, Rare diseases

Aliases & Classifications for Rare Tumor

MalaCards integrated aliases for Rare Tumor:

Name: Rare Tumor 58
Rare Neoplasm 58

Classifications:



External Ids:

UMLS via Orphanet 72 C0375111
Orphanet 58 ORPHA98057

Summaries for Rare Tumor

MalaCards based summary : Rare Tumor, also known as rare neoplasm, is related to desmoplastic small round cell tumor and paraganglioma. An important gene associated with Rare Tumor is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Cytoskeletal Signaling. The drugs leucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and liver, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Rare Tumor

Diseases in the Rare Tumor family:

Rare Eye Tumor

Diseases related to Rare Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 684, show less)
# Related Disease Score Top Affiliating Genes
1 desmoplastic small round cell tumor 32.3 EWSR1 DES
2 paraganglioma 31.8 SST RET KIT
3 spindle cell sarcoma 30.4 NF2 DES ACTC1
4 fibromatosis 30.2 DES ACTC1
5 leiomyosarcoma 30.2 KIT DES ACTC1
6 hemangioma 30.2 RET KIT ACTC1
7 lipomatosis, multiple 30.1 KIT EWSR1 DES
8 leiomyoma 30.1 KIT DES ACTC1
9 sarcoma, synovial 30.0 KIT EWSR1 DES
10 rhabdoid tumor predisposition syndrome 1 29.9 DES ACTC1
11 teratoma 29.9 SST KIT ACTC1
12 syringocystadenoma papilliferum 29.9 DES ACTC1
13 carcinosarcoma 29.9 KIT DES ACTC1
14 spindle cell lipoma 29.9 DES ACTC1
15 pulmonary blastoma 29.8 SST DES ACTC1
16 angiomyolipoma 29.7 KIT DES ACTC1
17 chondroma 29.7 KIT ACTC1
18 rhabdomyosarcoma 29.7 KIT EWSR1 DES ACTC1
19 congenital fibrosarcoma 29.7 EWSR1 DES ACTC1
20 parachordoma 29.7 DES ACTC1
21 desmoid tumor 29.7 KIT DES ACTC1
22 glomangioma 29.7 DES ACTC1
23 angiolipoma 29.6 DES ACTC1
24 alveolar soft part sarcoma 29.6 RET EWSR1 DES ACTC1
25 ossifying fibromyxoid tumor 29.6 DES ACTC1
26 hemangiopericytoma, malignant 29.6 KIT DES ACTC1
27 neurofibroma 29.6 NF2 KIT ACTC1
28 neurilemmoma 29.6 NF2 KIT DES ACTC1
29 follicular dendritic cell sarcoma 29.6 KIT FCER2 CR2
30 chondromyxoid fibroma 29.5 DES ACTC1
31 fibrous histiocytoma 29.5 KIT EWSR1 DES ACTC1
32 myoepithelial carcinoma 29.5 EWSR1 ACTC1
33 dermatofibrosarcoma protuberans 29.5 KIT DES ACTC1
34 malignant fibrous histiocytoma 29.5 KIT EWSR1 DES ACTC1
35 ewing sarcoma 29.5 RET KIT EWSR1 DES
36 embryonal rhabdomyosarcoma 29.4 EWSR1 DES ACTC1
37 perivascular epithelioid cell tumor 29.4 KIT DES ACTC1
38 adenosarcoma 29.4 KIT DES ACTC1
39 embryonal sarcoma 29.4 KIT DES
40 reticulum cell sarcoma 29.3 FCER2 DES CR2 ACTC1
41 neuroma 29.3 RET NF2 KIT
42 meningioma, familial 29.3 SST RET NF2 LATS2
43 sarcoma 29.2 RET NF2 KIT EWSR1 DES ACTC1
44 myxofibrosarcoma 29.2 KIT EWSR1 DES
45 perineurioma 29.2 KIT ACTC1
46 muscle cancer 29.2 KIT EWSR1 DES
47 inflammatory myofibroblastic tumor 29.2 KIT EWSR1 DES CR2 ACTC1
48 constipation 29.2 SST RET KIT EWSR1
49 pleomorphic liposarcoma 29.1 KIT EWSR1 DES ACTC1
50 malignant peripheral nerve sheath tumor 29.1 NF2 KIT ACTC1
51 smooth muscle tumor 29.0 KIT DES CR2 ACTC1
52 dendritic cell tumor 28.9 FSCN1 FCER2 CR2 ACTC1
53 fibrosarcoma 28.5 MMP2 KIT EWSR1 DES ACTC1
54 neuroblastoma 28.3 SST RET MMP2 KIT EWSR1
55 gastrointestinal stromal tumor 28.1 SST NF2 MMP2 KIT DES ACTC1
56 rare tumor of pancreas 12.2
57 rare tumor of gallbladder and extrahepatic biliary tract 12.1
58 rare tumor of small intestine 12.1
59 rare tumor of intestine 12.1
60 rare tumor of neuroepithelial tissue 12.1
61 rare tumor of salivary glands 12.1
62 hepatocellular carcinoma 11.6
63 pheochromocytoma 11.3
64 tumor of cranial and spinal nerves 11.2
65 chordoma 11.2
66 epithelioid hemangioendothelioma 11.2
67 thyroid carcinoma, familial medullary 11.2
68 atypical teratoid rhabdoid tumor 11.2
69 insulinoma 11.2
70 malignant acrospiroma 11.2
71 carney complex variant 11.2
72 acoustic neuroma 11.2
73 breast malignant phyllodes tumor 11.2
74 intraneural perineurioma 11.2
75 malignant teratoma 11.2
76 adenosarcoma of the uterus 11.2
77 large cell carcinoma with rhabdoid phenotype 10.9
78 hyperparathyroidism 2 with jaw tumors 10.8
79 hypothalamic hamartomas 10.8
80 papilloma of choroid plexus 10.8
81 wolffian duct adenoma 10.8
82 liver angiosarcoma 10.8
83 sertoli-leydig cell tumor 10.8
84 mast-cell sarcoma 10.8
85 adrenal carcinoma 10.8
86 ependymoblastoma 10.8
87 malignant syringoma 10.8
88 glucagonoma 10.8
89 goblet cell carcinoid 10.8
90 onychocytic matricoma 10.8
91 papillary glioneuronal tumors 10.8
92 primary melanoma of the central nervous system 10.8
93 vulvar sarcoma 10.4 EWSR1 ACTC1
94 ectopic cushing syndrome 10.4 SST RET
95 ewing sarcoma of bone 10.4 EWSR1 DES
96 fibroblastic rheumatism 10.4 DES ACTC1
97 ischemic fasciitis 10.4 DES ACTC1
98 binswanger's disease 10.4 SST ACTC1
99 extraskeletal ewing sarcoma 10.4 EWSR1 DES
100 benign metastasizing leiomyoma 10.4 DES ACTC1
101 cutaneous leiomyosarcoma 10.3 DES ACTC1
102 botryoid rhabdomyosarcoma 10.3 DES ACTC1
103 malignant giant cell tumor of soft parts 10.3 CR2 ACTC1
104 adrenal medulla cancer 10.3 SST RET
105 non-langerhans-cell histiocytosis 10.3 DES ACTC1
106 autonomic nervous system benign neoplasm 10.3 SST RET
107 peripheral nervous system benign neoplasm 10.2 SST RET
108 type c thymoma 10.2 SST KIT
109 gastric hemangioma 10.2 SST KIT
110 thymus clear cell carcinoma 10.2 KIT EWSR1
111 cerebellar angioblastoma 10.2 KIT EWSR1
112 rosai-dorfman disease 10.2 FSCN1 CR2
113 juvenile arthritis 10.2 FCER2 CR2
114 epithelioid leiomyosarcoma 10.2 DES ACTC1
115 retroperitoneal sarcoma 10.2 KIT EWSR1
116 liver leiomyoma 10.2 KIT CR2
117 skull base cancer 10.2 SST NF2
118 liver leiomyosarcoma 10.2 KIT CR2
119 skull base meningioma 10.2 SST NF2
120 endobronchial leiomyoma 10.2 KIT CR2
121 cranial nerve neoplasm 10.2 NF2 EWSR1
122 small intestine benign neoplasm 10.2 SST KIT
123 polymorphous low-grade adenocarcinoma 10.1 KIT ACTC1
124 active peptic ulcer disease 10.1 SST KIT
125 juvenile nasopharyngeal angiofibroma 10.1 KIT ACTC1
126 sarcomatoid mesothelioma 10.1 DES ACTC1
127 meckel diverticulum 10.1 SST KIT
128 adenoma 10.1
129 pseudosarcomatous fibromatosis 10.1 DES ACTC1
130 idiopathic neutropenia 10.1 HLA-DRB1 FCER2
131 pleomorphic lipoma 10.1
132 plexiform schwannoma 10.1 NF2 KIT
133 angiosarcoma 10.0
134 adenocarcinoma 10.0
135 intestinal obstruction 10.0 SST RET KIT
136 small intestine leiomyoma 10.0 NF2 KIT
137 cutaneous fibrous histiocytoma 10.0 DES ACTC1
138 hemangioendothelioma 10.0
139 osteogenic sarcoma 10.0
140 neuroendocrine carcinoma 10.0
141 dysphagia 10.0
142 ovarian fibrothecoma 10.0 KIT DES ACTC1
143 adult cystic nephroma 10.0 KIT DES ACTC1
144 nephroma 10.0 KIT DES ACTC1
145 pulmonary vein stenosis 10.0 KIT DES ACTC1
146 infantile myofibromatosis 10.0 DES ACTC1
147 mucinous stomach adenocarcinoma 10.0 NF2 KIT
148 light chain deposition disease 10.0 MMP2 ACTC1
149 chondrosarcoma 10.0
150 soft tissue sarcoma 10.0
151 b-lymphoblastic leukemia/lymphoma 10.0 RET KIT
152 meningioma, radiation-induced 10.0
153 spinal meningioma 10.0
154 mesenchymal cell neoplasm 10.0
155 liposarcoma 10.0
156 mucoepidermoid carcinoma 10.0
157 secretory meningioma 10.0
158 lymphoplasmacyte-rich meningioma 10.0
159 bronchiectasis 1 10.0 LATS2 HLA-DRB1
160 small cell carcinoma 9.9
161 granular cell tumor 9.9
162 benign mesothelioma 9.9
163 spindle cell carcinoma 9.9
164 renal cell carcinoma, nonpapillary 9.9
165 pancreatic cancer 9.9
166 melanoma, cutaneous malignant 10 9.9
167 fibroma 9.9
168 neuroendocrine tumor 9.9
169 melanoma 9.9
170 cystadenocarcinoma 9.9
171 embryoma 9.9
172 neurofibromatosis 9.9
173 cholangiocarcinoma 9.9
174 mucinous cystadenocarcinoma 9.9
175 plasmacytoma 9.9
176 intrahepatic cholangiocarcinoma 9.9
177 lymphoepithelioma-like carcinoma 9.9
178 thyroid carcinoma 9.9
179 osteoblastoma 9.8
180 glioblastoma multiforme 9.8
181 exophthalmos 9.8
182 glial tumor 9.8
183 hypertrophic pyloric stenosis 9.8 SST RET
184 peripheral nervous system neoplasm 9.8 NF2 KIT EWSR1
185 adrenocortical carcinoma, hereditary 9.8
186 oncocytoma 9.8
187 pleuropulmonary blastoma 9.8
188 nasopharyngeal carcinoma 9.8
189 adrenal cortical carcinoma 9.8
190 adrenal gland pheochromocytoma 9.8
191 lymphangioma 9.8
192 squamous cell carcinoma 9.8
193 gangliocytoma 9.8
194 basal cell carcinoma 9.8
195 cystadenoma 9.8
196 acinar cell carcinoma 9.8
197 astrocytoma 9.8
198 thymic carcinoma 9.8
199 rhabdoid cancer 9.8
200 adrenal cortical adenocarcinoma 9.8
201 pleomorphic adenoma 9.8
202 cavernous hemangioma 9.8
203 adenosquamous carcinoma 9.8
204 rare lymphatic malformation 9.8
205 dedifferentiated liposarcoma 9.8 KIT EWSR1 DES ACTC1
206 medulloblastoma 9.8
207 ovarian cancer 9.8
208 sarcoidosis 1 9.8
209 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
210 thymoma, familial 9.8
211 ameloblastoma 9.8
212 mucosal melanoma 9.8
213 lymphoma 9.8
214 adenoid cystic carcinoma 9.8
215 keratosis 9.8
216 endodermal sinus tumor 9.8
217 eyelid benign neoplasm 9.8
218 thymoma 9.8
219 verrucous carcinoma 9.8
220 clear cell sarcoma 9.8
221 ganglioneuroma 9.8
222 ganglioglioma 9.8
223 testicular yolk sac tumor 9.8
224 pulmonary sclerosing hemangioma 9.8
225 intracranial hypertension 9.8
226 glioma 9.8
227 rare soft tissue tumor 9.8
228 47,xyy 9.7
229 posttransplant acute limbic encephalitis 9.7
230 renal cell carcinoma, papillary, 1 9.7 RET NF2 KIT
231 breast cancer 9.7
232 epidermoid cysts 9.7
233 pilomatrixoma 9.7
234 esophageal cancer 9.7
235 mesothelioma, malignant 9.7
236 retinoblastoma 9.7
237 von hippel-lindau syndrome 9.7
238 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
239 connective tissue benign neoplasm 9.7
240 fibrous dysplasia 9.7
241 cholesteatoma of middle ear 9.7
242 squamous cell papilloma 9.7
243 central neurocytoma 9.7
244 breast fibroadenoma 9.7
245 benign breast phyllodes tumor 9.7
246 benign giant cell tumor 9.7
247 glomus tumor 9.7
248 papilloma 9.7
249 struma ovarii 9.7
250 chondroblastoma 9.7
251 mucinous adenocarcinoma 9.7
252 giant cell glioblastoma 9.7
253 cystic lymphangioma 9.7
254 papillary carcinoma 9.7
255 papillary adenoma 9.7
256 pleomorphic rhabdomyosarcoma 9.7
257 appendix adenocarcinoma 9.7
258 olfactory neuroblastoma 9.7
259 chordoid glioma 9.7
260 merkel cell carcinoma 9.7
261 thyroid gland medullary carcinoma 9.7
262 collecting duct carcinoma 9.7
263 breast angiosarcoma 9.7
264 familial retinoblastoma 9.7
265 benign ependymoma 9.7
266 pleomorphic xanthoastrocytoma 9.7
267 myoblastoma 9.7
268 epithelial-myoepithelial carcinoma 9.7
269 cellular ependymoma 9.7
270 basaloid squamous cell carcinoma 9.7
271 clear cell chondrosarcoma 9.7
272 epithelioid sarcoma 9.7
273 pancreatoblastoma 9.7
274 hepatoblastoma 9.7
275 malignant pleural mesothelioma 9.7
276 eccrine porocarcinoma 9.7
277 amyloidosis 9.7
278 nasal cavity benign neoplasm 9.7
279 germ cells tumors 9.7
280 neurofibromatosis, type i 9.7 SST RET NF2 KIT
281 leiomyoma, uterine 9.6
282 keratosis, seborrheic 9.6
283 lymphoma, hodgkin, classic 9.6
284 wilms tumor 5 9.6
285 lung cancer susceptibility 3 9.6
286 myxoid liposarcoma 9.6
287 autoimmune pancreatitis 9.6
288 villous adenoma 9.6
289 hydrocephalus 9.6
290 conn's syndrome 9.6
291 neutropenia 9.6
292 cholestasis 9.6
293 obstructive hydrocephalus 9.6
294 hypothyroidism 9.6
295 vascular cancer 9.6
296 calcinosis 9.6
297 nodular hidradenoma 9.6
298 syringoma 9.6
299 kidney cancer 9.6
300 cystic teratoma 9.6
301 transitional cell carcinoma 9.6
302 gliosarcoma 9.6
303 gallbladder cancer 9.6
304 skin benign neoplasm 9.6
305 germinoma 9.6
306 chondroblastic osteosarcoma 9.6
307 sertoli cell tumor 9.6
308 third ventricle chordoid glioma 9.6
309 hidradenoma 9.6
310 trophoblastic neoplasm 9.6
311 ganglioneuroblastoma 9.6
312 bone giant cell tumor 9.6
313 amelanotic melanoma 9.6
314 seminoma 9.6
315 sebaceous adenocarcinoma 9.6
316 sclerosing hemangioma 9.6
317 neurohypophysis granular cell tumor 9.6
318 epulis 9.6
319 middle ear adenoma 9.6
320 eccrine acrospiroma 9.6
321 kidney disease 9.6
322 well-differentiated liposarcoma 9.6
323 malignant mesenchymoma 9.6
324 myxoid chondrosarcoma 9.6
325 renal oncocytoma 9.6
326 eyelid carcinoma 9.6
327 amyloid tumor 9.6
328 inverted follicular keratosis 9.6
329 infiltrating lipoma 9.6
330 congenital epulis 9.6
331 nephrogenic adenoma 9.6
332 ceruminoma 9.6
333 appendicitis 9.6
334 in situ carcinoma 9.6
335 skin melanoma 9.6
336 hypopituitarism 9.6
337 pulmonary embolism 9.6
338 hypoglycemia 9.6
339 carcinoid syndrome 9.6
340 desmoplastic infantile ganglioglioma 9.6
341 lipoblastoma 9.6
342 osteochondroma 9.6
343 pseudoangiomatous stromal hyperplasia 9.6
344 rosette-forming glioneuronal tumor 9.6
345 subependymoma 9.6
346 thymic epithelial tumor 9.6
347 back pain 9.6
348 rare cardiac tumor 9.6
349 thymic epithelial neoplasm 9.6
350 histiocytic sarcoma 9.6
351 thyroid tumor 9.6
352 intussusception 9.6
353 kaposi sarcoma 9.6
354 melanosis, neurocutaneous 9.6
355 parathyroid carcinoma 9.6
356 hereditary lymphedema i 9.6
357 pleural lipoma 9.6
358 varicocele 9.6
359 hyperparathyroidism 9.6
360 melanotic neuroectodermal tumor 9.6
361 endocrine gland cancer 9.6
362 papillary serous adenocarcinoma 9.6
363 leydig cell tumor 9.6
364 neurilemmoma of the fifth cranial nerve 9.6
365 extraosseous osteosarcoma 9.6
366 peripheral osteosarcoma 9.6
367 bone osteosarcoma 9.6
368 central nervous system cancer 9.6
369 cervical adenocarcinoma 9.6
370 reticulohistiocytic granuloma 9.6
371 clear cell adenocarcinoma 9.6
372 angiokeratoma 9.6
373 apocrine adenocarcinoma 9.6
374 monophasic synovial sarcoma 9.6
375 gallbladder squamous cell carcinoma 9.6
376 gastric teratoma 9.6
377 aggressive digital papillary adenocarcinoma 9.6
378 cellular myxoid liposarcoma 9.6
379 cutaneous liposarcoma 9.6
380 adrenal neuroblastoma 9.6
381 benign intermediate mesothelioma 9.6
382 kidney fibrosarcoma 9.6
383 bartholin's gland adenocarcinoma 9.6
384 central epithelioid sarcoma 9.6
385 parathyroid adenoma 9.6
386 mature gastric teratoma 9.6
387 dicer1-related pleuropulmonary blastoma cancer predisposition syndrome 9.6
388 erythroplakia 9.6
389 littoral cell angioma of the spleen 9.6
390 oral cancer 9.6
391 pituitary tumors 9.6
392 primary peritoneal carcinoma 9.6
393 high-grade astrocytoma 9.6
394 myopericytoma 9.6
395 rare benign ovarian tumor 9.6
396 intravascular large b-cell lymphoma 9.6
397 burkitt lymphoma 9.5
398 periodic fever, familial, autosomal dominant 9.5
399 li-fraumeni syndrome 9.5
400 teratoma, ovarian 9.5
401 nephrolithiasis, calcium oxalate 9.5
402 familial adenomatous polyposis 1 9.5
403 strabismus 9.5
404 thrombophilia due to thrombin defect 9.5
405 thyroid cancer, nonmedullary, 1 9.5
406 wilms tumor 1 9.5
407 lipoid congenital adrenal hyperplasia 9.5
408 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.5
409 arachnoid cysts, intracranial 9.5
410 mycosis fungoides 9.5
411 myeloma, multiple 9.5
412 osteoid osteoma 9.5
413 rhabdomyosarcoma 2 9.5
414 testicular germ cell tumor 9.5
415 ataxia and polyneuropathy, adult-onset 9.5
416 kearns-sayre syndrome 9.5
417 prostatic hyperplasia, benign 9.5
418 gallbladder disease 1 9.5
419 branchiootic syndrome 1 9.5
420 carney triad 9.5
421 lymphoma, non-hodgkin, familial 9.5
422 lymphangioleiomyomatosis 9.5
423 endometrial cancer 9.5
424 li-fraumeni syndrome 2 9.5
425 hepatitis c virus 9.5
426 testicular microlithiasis 9.5
427 histiocytoma, angiomatoid fibrous 9.5
428 chondrosarcoma, extraskeletal myxoid 9.5
429 cholangitis, primary sclerosing 9.5
430 hyperprolactinemia 9.5
431 pachyonychia congenita 3 9.5
432 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.5
433 familial adenomatous polyposis 9.5
434 diffuse large b-cell lymphoma 9.5
435 mantle cell lymphoma 9.5
436 large cell neuroendocrine carcinoma 9.5
437 extra-adrenal pheochromocytoma 9.5
438 ductal carcinoma in situ 9.5
439 central nervous system primitive neuroectodermal neoplasm 9.5
440 omphalocele 9.5
441 nut midline carcinoma 9.5
442 hepatoid adenocarcinoma 9.5
443 mucositis 9.5
444 malignant epithelioid hemangioendothelioma 9.5
445 thyroid lymphoma 9.5
446 ampulla of vater cancer 9.5
447 ampulla of vater neoplasm 9.5
448 gastric leiomyoma 9.5
449 osteonecrosis 9.5
450 esophageal lipoma 9.5
451 sialadenitis 9.5
452 lipoma of colon 9.5
453 renal hypertension 9.5
454 prostatic hypertrophy 9.5
455 miliaria rubra 9.5
456 appendiceal neoplasm 9.5
457 hemopericardium 9.5
458 horner's syndrome 9.5
459 cardiac tamponade 9.5
460 penile benign neoplasm 9.5
461 choledocholithiasis 9.5
462 pericardial effusion 9.5
463 multicentric reticulohistiocytosis 9.5
464 visual epilepsy 9.5
465 plica syndrome 9.5
466 pancytopenia 9.5
467 olecranon bursitis 9.5
468 acute leukemia 9.5
469 pyloric stenosis 9.5
470 sialolithiasis 9.5
471 bladder leiomyoma 9.5
472 diarrhea 9.5
473 endometrial stromal nodule 9.5
474 miliaria 9.5
475 anus cancer 9.5
476 toxic shock syndrome 9.5
477 frozen shoulder 9.5
478 oligospermia 9.5
479 sclerosing cholangitis 9.5
480 prostatitis 9.5
481 pneumothorax 9.5
482 cystitis 9.5
483 islet cell tumor 9.5
484 ossifying fibroma 9.5
485 vaginal yolk sac tumor 9.5
486 fallopian tube carcinoma 9.5
487 rectum lymphoma 9.5
488 hepatitis b 9.5
489 hyperostosis 9.5
490 vulvar melanoma 9.5
491 central nervous system sarcoma 9.5
492 urethra leiomyoma 9.5
493 thrombocytosis 9.5
494 glandular cystitis 9.5
495 larynx cancer 9.5
496 myoepithelioma 9.5
497 adenofibroma 9.5
498 myoma 9.5
499 pigmented villonodular synovitis 9.5
500 synovitis 9.5
501 capillary hemangioma 9.5
502 bilirubin metabolic disorder 9.5
503 larynx sarcoma 9.5
504 prostatic adenoma 9.5
505 endometriosis 9.5
506 acute pancreatitis 9.5
507 bursitis 9.5
508 testicular cancer 9.5
509 breast neuroendocrine neoplasm 9.5
510 papillary adenocarcinoma 9.5
511 serous cystadenocarcinoma 9.5
512 tenosynovial giant cell tumor 9.5
513 keratoacanthoma 9.5
514 fallopian tube serous papilloma 9.5
515 neurilemmomatosis 9.5
516 spindle cell rhabdomyosarcoma 9.5
517 teratocarcinoma 9.5
518 embryonal carcinoma 9.5
519 histiocytosis 9.5
520 breast disease 9.5
521 cellulitis 9.5
522 signet ring cell adenocarcinoma 9.5
523 pseudomyxoma peritonei 9.5
524 epithelioid trophoblastic tumor 9.5
525 placental site trophoblastic tumor 9.5
526 ovarian mucinous adenocarcinoma 9.5
527 conus medullaris neoplasm 9.5
528 skin disease 9.5
529 bladder adenocarcinoma 9.5
530 extramedullary plasmacytoma 9.5
531 pleural empyema 9.5
532 craniopharyngioma 9.5
533 medullomyoblastoma 9.5
534 thrombophlebitis 9.5
535 linitis plastica 9.5
536 pancreatic cystadenocarcinoma 9.5
537 cervical carcinosarcoma 9.5
538 systemic scleroderma 9.5
539 clear cell meningioma 9.5
540 kidney sarcoma 9.5
541 angiomyoma 9.5
542 erdheim-chester disease 9.5
543 myofibroma 9.5
544 somatostatinoma 9.5
545 chromophobe renal cell carcinoma 9.5
546 mesenchymal chondrosarcoma 9.5
547 extraosseous chondrosarcoma 9.5
548 intraocular retinoblastoma 9.5
549 venous hemangioma 9.5
550 breast metaplastic carcinoma 9.5
551 histiocytoid hemangioma 9.5
552 medulloepithelioma 9.5
553 middle ear carcinoma 9.5
554 bronchiolo-alveolar adenocarcinoma 9.5
555 pancreatitis 9.5
556 pineal parenchymal tumor of intermediate differentiation 9.5
557 malignant granular cell myoblastoma 9.5
558 myxopapillary ependymoma 9.5
559 ovarian cyst 9.5
560 leiomyomatosis 9.5
561 plexiform neurofibroma 9.5
562 urinary tract obstruction 9.5
563 benign struma ovarii 9.5
564 esophagus leiomyosarcoma 9.5
565 prostate leiomyosarcoma 9.5
566 vagina leiomyosarcoma 9.5
567 testicular granulosa cell tumor 9.5
568 gingival hypertrophy 9.5
569 pulmonary coin lesion 9.5
570 clear cell adenoma 9.5
571 lung oat cell carcinoma 9.5
572 clear cell hidradenoma 9.5
573 spiradenoma 9.5
574 biphasic synovial sarcoma 9.5
575 testicular germ cell cancer 9.5
576 mature teratoma 9.5
577 ovarian germ cell teratoma 9.5
578 eccrine papillary adenocarcinoma 9.5
579 spinal cancer 9.5
580 esophageal adenosquamous carcinoma 9.5
581 pancreatic adenosquamous carcinoma 9.5
582 spindle cell liposarcoma 9.5
583 intravenous leiomyomatosis 9.5
584 pancreatic acinar cell adenocarcinoma 9.5
585 ovarian serous cystadenocarcinoma 9.5
586 spermatocytoma 9.5
587 nephrolithiasis 9.5
588 meningeal melanocytoma 9.5
589 ovarian mucinous neoplasm 9.5
590 ovarian carcinosarcoma 9.5
591 ovarian small cell carcinoma 9.5
592 metanephric adenoma 9.5
593 plasma cell neoplasm 9.5
594 adrenal adenoma 9.5
595 diffuse idiopathic skeletal hyperostosis 9.5
596 malignant triton tumor 9.5
597 juvenile pilocytic astrocytoma 9.5
598 b-cell lymphoma 9.5
599 laryngeal small cell carcinoma 9.5
600 langerhans cell sarcoma 9.5
601 thyroiditis 9.5
602 transitional meningioma 9.5
603 esophageal tuberculosis 9.5
604 pulmonary artery leiomyosarcoma 9.5
605 adenomatoid tumor 9.5
606 subareolar duct papillomatosis 9.5
607 lymphoepithelioma-like thymic carcinoma 9.5
608 cholangiolocellular carcinoma 9.5
609 placenta disease 9.5
610 end stage renal disease 9.5
611 testicular spermatocytic seminoma 9.5
612 malignant spiradenoma 9.5
613 congenital granular cell tumor 9.5
614 kidney angiomyolipoma 9.5
615 actinomycosis 9.5
616 reticulosarcoma 9.5
617 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.5
618 vasculitis 9.5
619 myeloid sarcoma 9.5
620 crohn's disease 9.5
621 orbital disease 9.5
622 mechanical strabismus 9.5
623 diabetes insipidus 9.5
624 cholangitis 9.5
625 villonodular synovitis 9.5
626 hypereosinophilic syndrome 9.5
627 dicer1 tumor predisposition 9.5
628 48,xyyy 9.5
629 abdominal cystic lymphangioma 9.5
630 ameloblastic carcinoma 9.5
631 amyloidosis aa 9.5
632 anaplastic plasmacytoma 9.5
633 anaplastic pleomorphic xanthoastrocytoma 9.5
634 bowen's disease 9.5
635 bronchogenic cyst 9.5
636 diffuse gastric cancer 9.5
637 endolymphatic sac tumor 9.5
638 lymphomatoid granulomatosis 9.5
639 malakoplakia 9.5
640 nephrogenic systemic fibrosis 9.5
641 odontogenic myxoma 9.5
642 polymyositis 9.5
643 precocious puberty 9.5
644 primary bone cancer 9.5
645 primary malignant melanoma of the cervix 9.5
646 sacrococcygeal teratoma 9.5
647 splenomegaly 9.5
648 tetraploidy 9.5
649 tièche-jadassohn nevus 9.5
650 urachal adenocarcinoma 9.5
651 uterine sarcoma 9.5
652 warthin tumor 9.5
653 central precocious puberty 9.5
654 angiomatosis 9.5
655 headache 9.5
656 paraneoplastic syndromes 9.5
657 seizure disorder 9.5
658 syncope 9.5
659 syringohydromyelia 9.5
660 mixed germ cell tumor 9.5
661 undifferentiated embryonal sarcoma of the liver 9.5
662 b-cell non-hodgkin lymphoma 9.5
663 calcifying aponeurotic fibroma 9.5
664 pituicytoma 9.5
665 neuronal tumor 9.5
666 rare vascular tumor 9.5
667 carcinosarcoma of the cervix uteri 9.5
668 virus-associated trichodysplasia spinulosa 9.5
669 elastofibroma dorsi 9.5
670 lymphoepithelial-like carcinoma 9.5
671 well-differentiated fetal adenocarcinoma of the lung 9.5
672 onychomatricoma 9.5
673 composite hemangioendothelioma 9.5
674 retiform hemangioendothelioma 9.5
675 mucinous adenocarcinoma of the appendix 9.5
676 mucinous adenocarcinoma of ovary 9.5
677 solid pseudopapillary carcinoma of pancreas 9.5
678 mucinous cystadenocarcinoma of the pancreas 9.5
679 acinar cell carcinoma of pancreas 9.5
680 orbital leiomyoma 9.5
681 combined hepatocellular carcinoma and cholangiocarcinoma 9.5
682 plasma cell tumor 9.5
683 endometrial stromal sarcoma 9.2 MMP2 KIT EWSR1 DES ACTC1
684 gastric adenocarcinoma 8.8 SST MMP2 LATS2 KIT HLA-DRB1

Graphical network of the top 20 diseases related to Rare Tumor:



Diseases related to Rare Tumor

Symptoms & Phenotypes for Rare Tumor

MGI Mouse Phenotypes related to Rare Tumor:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.85 ACTC1 CR2 DES FCER2 KIT LATS2
2 mortality/aging MP:0010768 9.7 ACTC1 CR2 DES FCER2 FSCN1 KIT
3 muscle MP:0005369 9.1 ACTC1 DES KIT LATS2 MMP2 RET

Drugs & Therapeutics for Rare Tumor

Drugs for Rare Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 116, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
2
Pemetrexed Approved, Investigational Phase 2, Phase 3 137281-23-3, 150399-23-8 60843 446556
3
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
7
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
8
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
9 Vitamins Phase 2, Phase 3
10 Vitamin B Complex Phase 2, Phase 3
11 Folic Acid Antagonists Phase 2, Phase 3
12 Folate Phase 2, Phase 3
13 Vitamin B9 Phase 2, Phase 3
14 Vitamin B 12 Phase 2, Phase 3
15 Vitamin B12 Phase 2, Phase 3
16
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Mitotane Approved Phase 2 53-19-0 4211
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
21
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
22
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
23
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
24
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
25
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
26
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
rituximab Approved Phase 2 174722-31-7 10201696
29
Olaparib Approved Phase 2 763113-22-0 23725625
30
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
31
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
32
Durvalumab Approved, Investigational Phase 2 1428935-60-7
33
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Osimertinib Approved Phase 2 1421373-65-0 71496458
35
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
36
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Ifosfamide Approved Phase 2 3778-73-2 3690
39
Gemcitabine Approved Phase 2 95058-81-4 60750
40
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
41
Levodopa Approved Phase 2 59-92-7 6047
42
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
43
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
44
Imiquimod Approved, Investigational Phase 1, Phase 2 99011-02-6 57469
45
Tremelimumab Investigational Phase 2 745013-59-6
46
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
47
Liposomal doxorubicin Phase 2 31703
48 Etoposide phosphate Phase 2
49 polysaccharide-K Phase 2
50
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
51 Antineoplastic Agents, Immunological Phase 2
52 Cola Phase 2
53 Antidotes Phase 2
54 Protective Agents Phase 2
55 Antitubercular Agents Phase 2
56 Antioxidants Phase 2
57 Chelating Agents Phase 2
58 Anti-Bacterial Agents Phase 2
59 sodium thiosulfate Phase 2
60 Hormone Antagonists Phase 2
61 Antineoplastic Agents, Hormonal Phase 2
62 Estrogen Receptor Antagonists Phase 2
63 Estrogen Antagonists Phase 2
64 Estrogen Receptor Modulators Phase 2
65 Estrogens Phase 2
66 Hormones Phase 2
67 Alkylating Agents Phase 2
68 Antirheumatic Agents Phase 2
69 Bendamustine Hydrochloride Phase 2
70 Protein Kinase Inhibitors Phase 2
71 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
72 Imatinib Mesylate Phase 2 220127-57-1 123596
73 Albumin-Bound Paclitaxel Phase 2
74
Isophosphamide mustard Phase 2 0
75 Immunosuppressive Agents Phase 2
76 Immunologic Factors Phase 2
77 Anti-Infective Agents Phase 2
78 Antiviral Agents Phase 2
79 Antimetabolites Phase 2
80 Immunoglobulins Phase 2
81 Antibodies Phase 2
82 Antiparkinson Agents Phase 2
83 Neurotransmitter Agents Phase 2
84 Dihydroxyphenylalanine Phase 2
85 Dopamine Agents Phase 2
86 calcitonin Phase 2
87 Katacalcin Phase 2
88 Interferon-alpha Phase 1, Phase 2
89 Adjuvants, Immunologic Phase 1, Phase 2
90 Vaccines Phase 1, Phase 2
91 interferons Phase 1, Phase 2
92
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
93
Lenalidomide Approved Phase 1 191732-72-6 216326
94
Penciclovir Approved Phase 1 39809-25-1 4725
95
Epinephrine Approved, Vet_approved Phase 1 51-43-4 5816
96
Racepinephrine Approved Phase 1 329-65-7 838
97 Angiogenesis Inhibitors Phase 1
98 Antibodies, Monoclonal Phase 1
99 Ch14.18 monoclonal antibody Phase 1
100 Epinephryl borate Phase 1
101
Propranolol Approved, Investigational 525-66-6 4946
102
Methotrexate Approved 59-05-2, 1959-05-2 126941
103
Procarbazine Approved, Investigational 671-16-9 4915
104
Cytarabine Approved, Experimental, Investigational 147-94-4, 65-46-3 6253
105
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
106
Dactinomycin Approved, Investigational 50-76-0 457193 2019
107 Fluorodeoxyglucose F18
108 Adrenergic beta-Antagonists
109 Hematinics
110 Liver Extracts
111 Micronutrients
112 Trace Elements
113 Nutrients
114 Dermatologic Agents
115 Tubulin Modulators
116 Antimitotic Agents

Interventional clinical trials:

(showing 45, show less)
# Name Status NCT ID Phase Drugs
1 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
2 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
3 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
4 Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event Recruiting NCT03239015 Phase 2 Gefitinib;Erlotinib;Afatinib;Trastuzumab;Oxazolidine;Olaparib;Everolimus;Cabozantinib;Vemurafenib;Dabrafenib;Palbociclib
5 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes Recruiting NCT04171700 Phase 2 Rucaparib
6 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
7 A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors Recruiting NCT02938793 Phase 2 Durvalumab;Tremelimumab
8 Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Recruiting NCT03870399 Phase 2 Tamoxifen
9 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study Active, not recruiting NCT02853370 Phase 2 Bendamustine and Rituximab
10 Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China Not yet recruiting NCT04423185 Phase 2 Osimertinib 80 MG;Dacomitinib 45 MG;Alectinib 150 MG;Crizotinib 250 MG;Pyrotinib 160/80 MG;Imatinib 400 MG;Olaparib 150 MG;Palbociclib 125mg;Vemurafenib 240 MG;Sintilimab 100MG;Atezolizumab 1200 MG;Durvalumab 500 MG
11 A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study Suspended NCT01627795 Phase 1, Phase 2 Oshadi D and Oshadi R
12 Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP Suspended NCT02817958 Phase 2 Chemotherapy TIP
13 Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients Terminated NCT02472080 Phase 2 gemcitabine -oxaliplatine combination
14 Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy Terminated NCT01383746 Phase 1, Phase 2
15 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
16 Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma Terminated NCT01191034 Phase 1, Phase 2 Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
17 Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma Terminated NCT01723813 Phase 1, Phase 2
18 Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors Completed NCT00183833 Phase 1 capecitabine, imatinib mesylate
19 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study) Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
20 A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide Recruiting NCT02573896 Phase 1 Ch14.18;Lenalidomide
21 A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma Terminated NCT01832974 Phase 1 IL-13-PE
22 Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma Unknown status NCT01594203
23 Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors Completed NCT02334930
24 Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma Completed NCT03178409
25 A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00594815 Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
26 Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study Completed NCT03774862
27 Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development Completed NCT00340353
28 Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Completed NCT02015026
29 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
30 Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC) Completed NCT03419286
31 International Pediatric Adrenocortical Tumor Registry Recruiting NCT00700414
32 Natural History Study of Children and Adults With Chordoma Recruiting NCT03910465
33 Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors Recruiting NCT03739827
34 Neuroblastoma Biology Studies Recruiting NCT00904241
35 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
36 Clinico-biological Study/Characterization of Rhabdomyosarcoma in AYA (Adolescents and Young Adults, 15-25-year-old Patients) Recruiting NCT03462888
37 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
38 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732
39 A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer Active, not recruiting NCT01802567
40 Family Study of Head and Neck Cancers in Taiwan Active, not recruiting NCT00342147
41 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903
42 Retrospective Study of Optimal Methods of Disease Progression and Survival Analysis in Children and Adults With Adrenocortical Cancer (ACC) Enrolling by invitation NCT04358107
43 Measurement of Circulating Tumor Cells in Prostate Cancer Not yet recruiting NCT04101305
44 Rare Tumor Case Review Terminated NCT00229879
45 Topical Anesthesia to Decrease the Trigeminal-Cardiac Reflex During Intra-arterial Injection of Chemotherapy for Retinoblastoma in Children. Withdrawn NCT02955524 Early Phase 1 Tetracaine 0.5%;Lidocaine hydrochloride ophthalmic gel 3.5%

Search NIH Clinical Center for Rare Tumor

Genetic Tests for Rare Tumor

Anatomical Context for Rare Tumor

MalaCards organs/tissues related to Rare Tumor:

40
Breast, Pancreas, Liver, Thyroid, Lung, Bone, Kidney

Publications for Rare Tumor

Articles related to Rare Tumor:

(showing 10206, show less)
# Title Authors PMID Year
1
Scrotal leiomyoma a rare benign intra-scrotal mass could lead to unnecessary orchiectomy. 61
32368497 2020
2
Successful surgical management of recurrent urachal adenocarcinoma: A case report. 61
32322529 2020
3
Intra-scrotal extra-testicular schwannoma: A case report and literature review. 61
32373470 2020
4
A tale of autoimmunity: thymoma, thymectomy, and systemic lupus erythematosus. 61
32277368 2020
5
Mixed adenoneuroendocrine carcinoma of the gallbladder, amphicrine type: Case report and review of literature. 61
32534704 2020
6
Low-Grade Myofibroblastic Sarcoma Demonstrated on 99mTc-MDP Bone Scan and 18F-FDG PET/CT. 61
32433178 2020
7
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. 61
32422573 2020
8
Primary skull base neuroendocrine carcinoma-a case report and review of literature. 61
32461779 2020
9
Leiomyosarcoma of renal vein: A case report. 61
32322515 2020
10
Hemoptysis as the first symptom in the diagnosis of metastatic choriocarcinoma in the third trimester of pregnancy: A case report. 61
32426244 2020
11
Benign testicular cavernous hemangioma presenting with acute onset: A case report. 61
32454970 2020
12
Development and internal validation of a diagnostic score for gastric linitis plastica. 61
32103376 2020
13
A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. 61
32558385 2020
14
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease. 61
32090658 2020
15
Epstein-Barr Virus positive inflammatory follicular dendritic cell sarcoma presenting as solitary colonic mass: two rare cases and literature review. 61
32506505 2020
16
Hepatic adrenal adenoma-rare tumor on right lobe of liver: a case report and literature review. 61
32522174 2020
17
Gastric pyloric gland adenoma resembling a submucosal tumor: A case report. 61
32548171 2020
18
Pituicytoma associated with Cushing's disease: a case report and literature review. 61
32577204 2020
19
Hepatic Epithelioid Hemangioendothelioma as a Rare Indication for Liver Transplantation. 61
32241636 2020
20
Male adnexal tumor of probable Wolffian origin: a new entity in males similar to female adnexal tumor of probable Wolffian origin. 61
32506155 2020
21
Sex differences in solid pseudopapillary neoplasm of the pancreas: A population-based study. 61
32578384 2020
22
Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations. 61
32570879 2020
23
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. 61
32571725 2020
24
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. 61
32483241 2020
25
Tall cell carcinoma of the breast with reversed polarity (TCCRP) with mutations in the IDH2 and PIK3CA genes: a case report. 61
32474846 2020
26
The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases. 61
32555264 2020
27
Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. 61
32512881 2020
28
Myointimoma of the penis. 61
32488208 2020
29
An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013. 61
31796950 2020
30
Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice. 61
31855495 2020
31
Lung cancer from a focal bulla into thin-walled adenocarcinoma with ground glass opacity - an observation for more than 10 years: A case report. 61
32548161 2020
32
Primary hepatic carcinoma with inhibin positivity in a young male patient: a rare tumor previously only reported in females-case report and review of literature. 61
32533342 2020
33
Conjunctival Melanoma: Current Treatments and Future Options. 61
31965542 2020
34
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. 61
32495499 2020
35
Analysis of Characteristics and Survival of Primary Cutaneous Adenoid Cystic Carcinoma of the Head and Neck. 61
32567392 2020
36
Adenoid cystic carcinoma of trachea: long-term disease control after endoscopic surgery and radiotherapy. 61
31793391 2020
37
Myxofibrosarcoma of the scalp with difficult preoperative diagnosis: A case report and review of the literature. 61
32548167 2020
38
Pancreatic metastasis of Merkel-cell carcinoma: a rare neoplasm of the pancreas. 61
32379470 2020
39
Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids. 61
32124226 2020
40
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. 61
32363992 2020
41
A rare case of primary rectal choriocarcinoma and review of the literature. 61
31547751 2020
42
Perivascular Epithelioid Cell Tumor of the Urinary Bladder: A Systematic Review. 61
31865807 2020
43
Juvenile Granulosa Cell Tumors of the Ovary. 61
32561911 2020
44
Malignant fibrous histiocytoma of bone: A survival analysis from the National Cancer Database. 61
32133661 2020
45
[Long-term Survival Malignant Fibrous Histiocytoma of the Chest Wall by Postoperative Multidisciplinary Therapy;Report of a Case]. 61
32475976 2020
46
Alveolar soft part sarcoma of the lateral rectus muscle: Suture technique to prevent postoperative strabismus. 61
32322745 2020
47
Anaplastic thyroid carcinoma with rhabdoid phenotype: An unusual case and a comprehensive review. 61
32515545 2020
48
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma. 61
32504188 2020
49
Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target. 61
32404987 2020
50
Patients With Acinar Cell Carcinoma of the Pancreas After 2005: A Large Population Study. 61
32541633 2020
51
Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand. 61
31396884 2020
52
Isolated colonic neurofibroma, a rare tumor: A case report and review of literature. 61
32518783 2020
53
Aggressive angiomyxoma in an 11-year-old boy - diagnostic and therapeutic dilemmas: an unusual case report and review of the literature. 61
32479833 2020
54
Association between prognosis and complete resection in primary cutaneous myoepithelial carcinoma: two case presentations and literature review. 61
32369232 2020
55
Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature. 61
32354920 2020
56
Squamous cell carcinoma of the ear canal infiltrating the temporal bone: A case report. 61
32376194 2020
57
Pathology features and the results of treatment of two cases of posterior choroidal leiomyoma. 61
32448235 2020
58
Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. 61
32397993 2020
59
A nomogram to predict metastasis of soft tissue sarcoma of the extremities. 61
32481285 2020
60
MED12 exon 2 mutation is uncommon in intravenous leiomyomatosis: clinicopathologic features and molecular study. 61
32240666 2020
61
Comprehensive Immune Profiling of Medullary Thyroid Cancer. 61
32242507 2020
62
Malignant adenomyoepithelioma of the breast. 61
32472226 2020
63
Hepatic metastasis in Frantz's tumor: A case report. 61
32473553 2020
64
"Sample-to-Answer" Detection of Rare ctDNA Mutation from 2 mL Plasma with a Fully Integrated DNA Extraction and Digital Droplet PCR Microdevice for Liquid Biopsy. 61
32323972 2020
65
Combining Inertial Microfluidics with Cross-Flow Filtration for High-Fold and High-Throughput Passive Volume Reduction. 61
32297510 2020
66
Cystic liver neoplams: A single centre experience and literature review. 61
32439140 2020
67
Expanding Awareness of the Distribution and Biologic Potential of Ectomesenchymal Chondromyxoid Tumor. 61
32372271 2020
68
Melanocytic lesion in children and adolescents: an Italian observational study. 61
32451385 2020
69
Recent Topics Concerning Combined Hepatocellular Cholangiocarcinoma. 61
32378534 2020
70
Retrospective study of COL1A1-PDGFB fusion gene-positive dermatofibrosarcoma protuberans in Kumamoto University. 61
32460387 2020
71
Trochlear Schwannoma Arising from Transition Zone of Nerve Sheath in the Pineal Region: Case Report and Review of the Literature. 61
32059963 2020
72
Cardiac Myxoma as a Rare Cause of Pediatric Arterial Ischemic Stroke: Case Report and Literature Review. 61
32369836 2020
73
Adenoid Cystic Carcinoma of Bartholin's Gland: What Is the Best Approach? 61
32408297 2020
74
Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin's glands reveals potential new routes for targeted therapies: a case report. 61
32466769 2020
75
Osteoblastoma in the occipital bone: A case report of a rare tumor in the calvarium. 61
32215163 2020
76
Primary undifferentiated spindle cell sarcoma obstructing the right ventricular outflow tract. 61
32366268 2020
77
Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. 61
32405521 2020
78
A clinical analysis of sinonasal squamous cell carcinoma: a comparison of de novo squamous cell carcinoma and squamous cell carcinoma arising from inverted papilloma. 61
32400256 2020
79
Primary left ventricular neuroendocrine tumor in a middle-aged female: a case report. 61
32566590 2020
80
Conjunctival Adenosquamous Carcinoma Lacks MAML2 Translocation: A Variant of Squamous Cell Carcinoma With Mucoepidermoid Differentiation and Aggressive Behavior? 61
32476556 2020
81
Atypical extraventricular neurocytoma: A case report. 61
32415952 2020
82
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. 61
31969335 2020
83
Polyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma. 61
31759946 2020
84
Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report. 61
32481365 2020
85
Recurrence of ovarian squamous cell carcinoma with MET gene copy number variation: a case report and review of literature. 61
32475345 2020
86
Leiomyosarcoma of the inferior vena cava: A case report of a rare tumor entity. 61
32438337 2020
87
Inferior Vena Cava Leiomyosarcoma: What Method of Reconstruction for Which Type of Resection? 61
32445073 2020
88
Management and survival of patients with Mullerian adenosarcoma of the cervix without sarcomatous overgrowth desiring fertility preservation, a case report and review of the literature. 61
32181315 2020
89
Tracheal glomus tumor: An aggressive rare neoplasm. 61
32367860 2020
90
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome. 61
32345664 2020
91
Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways. 61
32429446 2020
92
Primary transitional cell carcinoma of the fallopian tube: A case report and literature review. 61
32481467 2020
93
Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin. 61
32258333 2020
94
Long-term outcomes of skull base chordoma treated with high-dose carbon-ion radiotherapy. 61
32472716 2020
95
Chondromesenchymal hamartomas in a 24-year-old male mimicking a posterior mediastinal tumor and a 5-month-old boy with postoperative disseminated intravascular coagulation: two case reports. 61
32398154 2020
96
Bulky cervical tumor showing mixed unique clusters in cervical cytology. 61
32415871 2020
97
TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. 61
32404956 2020
98
Epstein-Barr virus associated hepatic smooth muscle tumor in a patient with acquired immunodeficiency syndrome: A case report. 61
32358363 2020
99
Epidemiology and Risk Factors of Osteosarcoma. 61
32400205 2020
100
Review of treatment modalities and outcomes of patients with basal cell adenocarcinoma. 61
32093975 2020
101
Management and Reconstruction of a Massive Neonatal Neck Teratoma. 61
32195831 2020
102
Malignant perivascular epithelioid tumor of the vagina: Report of a rare case with brief review of literature. 61
32134210 2020
103
Clinical Characteristics and Surgical Features of Intracranial Fibrosarcoma. 61
32049915 2020
104
Mesonephric adenocarcinoma of the uterine cervix with rare lung metastases: A case report and review of the literature. 61
32432147 2020
105